Delivery Order SPE2DB22D2206-SPE2DB26FDU96
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $13,037.95 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on October 23, 2025, with completion scheduled for October 24, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a $32,318.92 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $24,397.55 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on June 26, 2025, with an ultimate completion date of June 27, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $12,497.80 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $9,728.70 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $13.3K delivery order to AmerisourceBergen Drug Corp on May 8, 2025, for RINVOQ ER 15 mg tablets (30-count units). This competitive, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a $30,275.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be performed...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose) valued at $6,223.32 on September 19, 2025, with an ultimate completion date of September 22, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The order will be fulfilled at the vendor's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $13,565.47 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 21, 2025, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under a larger indefinite delivery contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a $3,678.58 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on April 23, 2025, with an ultimate completion date of April 24, 2025. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that enables the company to supply pharmaceutical...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB26FDU96Delivery Order
The Defense Logistics Agency awarded a $14,468.30 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on October 29, 2025, with an ultimate completion date of October 30, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, supplying medications, vaccines, medical devices, and specialized healthcare commodities to military and veteran healthcare systems. This delivery order for RINVOQ, a prescription medication used to treat rheumatoid arthritis and other inflammatory conditions, exemplifies the company's role in fulfilling routine pharmaceutical supply needs for the Defense Health Agency and other government healthcare customers. The award demonstrates AmerisourceBergen's continued capability to meet federal procurement requirements through open competition and its significance as a primary pharmaceutical vendor supporting the Department of Defense's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.5k | 10/29/25 |